In a market obsessed with sexy, fast-growing technology companies, a better long-term strategy may be to look for wallflowers. Wall Street's rally this year has been led by the tech world's most storied franchises, including Amazon.com, Apple and Facebook. That has dimmed investors' interest in many other companies, particularly those that are short on glamour or that face challenges reinvigorating their own growth.
Market capitalization: $8.0 billion
Annual sales: $10.4 billion
Estimated earnings growth: This year, 211%; next year, 25%
Price-earnings ratio: 36
Dividend yield: 1.5% Although energy stocks have recovered a bit from a nasty 18-month-long slide that started in the middle of 2014, the group remains depressed. And few stocks have been hit harder than Cenovus (symbol CVE, $9.66), which produces oil and gas, mostly in the tar sands of the Canadian province of Alberta.
Medical science hasn't yet won the war on cancer, but it is scoring important victories in battles against many forms of the dreaded disease. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks. Companies such as Medivation have fueled the renewed lure of striking it rich from novel cancer treatments.